Soligenix begins Phase III of dusquetide to treat oral mucositis

Soligenix Inc. (NASDAQ:SNGX) began the Phase III IDR-OM-02 (DOM-INNATE) trial of dusquetide (SGX94, SGX942) to treat severe oral mucositis (OM) in about 190 patients undergoing chemoradiation therapy (CRT) for head and neck cancer.

Patients receive placebo or twice-weekly 1.5 mg/kg IV dusquetide starting within 3 days of CRT initiation and continuing through 2 weeks post-CRT...